Publications by authors named "Helgi van de Velde"

87Publications

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.

Onco Targets Ther 2018 6;11:3869-3882. Epub 2018 Jul 6.

Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S150339DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039072PMC
July 2018

Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.

Clin Pharmacol Ther 2019 02 23;105(2):376-387. Epub 2018 Mar 23.

Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.1047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585617PMC
February 2019

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.

Clin Pharmacokinet 2017 11;56(11):1355-1368

Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, 40 Landsdowne Street , Cambridge, MA, 02139, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40262-017-0526-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648746PMC
November 2017

The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.

Br J Haematol 2016 08 5;174(3):368-81. Epub 2016 Jun 5.

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14058DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089628PMC
August 2016

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 Apr;374(17):1621-34

From University Hospital Hôtel Dieu, Nantes (P.M., C.T.), the Department of Hematology, Institut Paoli-Calmettes, Marseille (A.-M.S.), and the Department of Hematology and Cell Therapy, Hospital Saint Antoine, Paris (L.G.) - all in France; the Department of Haematology and Stem Cell Transplantation, St. István and St. László Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary (T.M.); the Department of Haemato-oncology and Bone Marrow Transplantation, Medical University of Lublin, and St. John's Cancer Center, Lublin, Poland (N.G.); Southern Alberta Cancer Research Institute, University of Calgary, Calgary (N.J.B.), and the Division of Hematology, Department of Medicine, University of Alberta, Edmonton (I.S.) - both in Canada; the Department of Hematology, Skåne University Hospital, Lund University, Lund, Sweden (M.H.); Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (L.P.); the Department of Haematology, Christchurch Hospital, Christchurch (P. Ganly), the Department of Haematology, Palmerston North Hospital, Palmerston North, Manawatu (B.W.B.), the Department of Haematology, Middlemore Hospital, Auckland (S.R.J.), and the Department of Haematology, North Shore Hospital, Auckland (D.R.S.) - all in New Zealand; the Department of Hematology, University Hospital Rigshospitalet, Copenhagen (P. Gimsing); Myeloma Unit, Division of Hematology, University of Turin, Turin (A.P.), and Seràgnoli Institute of Haematology, Bologna University School of Medicine, St. Orsola-Malpighi University Hospital, Bologna (M.C.) - both in Italy; the Division of Hematology, Mayo Clinic, Rochester, MN (S.K., F.K.B.); and Dana-Farber Cancer Institute, Boston (J.P.L., P.G.R.), and Millennium Pharmaceuticals, Cambridge (D.T.B., J.L., A.D.B., A.-M.H., H.V.) - both in Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1516282DOI Listing
April 2016

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

Clin Cancer Res 2016 Aug 22;22(16):4206-4214. Epub 2016 Mar 22.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987182PMC
August 2016

Development and validation of panoptic Meso scale discovery assay to quantify total systemic interleukin-6.

Br J Clin Pharmacol 2015 Oct 4;80(4):687-97. Epub 2015 Jun 4.

Oncology, Translational Research, Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, Pennsylvania.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bcp.12652
Publisher Site
http://dx.doi.org/10.1111/bcp.12652DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594705PMC
October 2015

Dose selection of siltuximab for multicentric Castleman's disease.

Cancer Chemother Pharmacol 2015 May 18;75(5):1037-45. Epub 2015 Mar 18.

Janssen Research & Development, LLC, Spring House, PA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2720-0DOI Listing
May 2015

The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.

Am J Hematol 2015 May 27;90(5):E86-91. Epub 2015 Feb 27.

Peter MacCallum Cancer Centre, East Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23967DOI Listing
May 2015

Use of a claims database to characterize and estimate the incidence rate for Castleman disease.

Leuk Lymphoma 2015 May 29;56(5):1252-60. Epub 2014 Sep 29.

Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.953145DOI Listing
May 2015

A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.

Clin Cancer Res 2014 Apr 21;20(8):2192-204. Epub 2014 Feb 21.

Authors' Affiliations: Institut de Cancérologie Gustave Roussy, Villejuif; Centre Francois Baclesse, CHU Côte de Nacre, Caen; Centre Léon Bérard Lyon, Lyon, France; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona; 12 de Octubre University Hospital, Madrid, Spain; Fox Chase Cancer Center, Philadelphia; Janssen Research & Development, Spring House, Pennsylvania; formerly University of Texas, MD Anderson Cancer Center, Houston, Texas; currently UC San Diego Moores Cancer Center, San Diego, California; Erasme University Hospital; Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, Brussels; AZ Sint-Augustinus, Antwerp; Janssen Research & Development, Beerse, Belgium; Southampton University Hospitals NHS Trust, Southampton; Western General Hospital, Edinburgh; University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; and Janssen Research & Development, Leiden, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2200DOI Listing
April 2014

Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.

Exp Neurol 2014 Mar 7;253:165-73. Epub 2014 Jan 7.

Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2013.12.020DOI Listing
March 2014

Antibody against tumor necrosis factor-α reduces bortezomib-induced allodynia in a rat model.

Anticancer Res 2013 Dec;33(12):5453-9

University of Milano Bicocca, via Cadore 48, 20900 Monza (MB), Italy.

View Article

Download full-text PDF

Source
December 2013

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma.

Cancer Chemother Pharmacol 2014 Jan 23;73(1):35-42. Epub 2013 Oct 23.

Division of Cancer Medicine, Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0429, Houston, TX, 77030, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2314-7DOI Listing
January 2014

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

J Clin Oncol 2013 Sep 29;31(26):3279-87. Epub 2013 Jul 29.

Pieter Sonneveld, Erasmus Medical Center, Rotterdam; Henk M. Lokhorst, Utrecht Medical Center, Utrecht, the Netherlands; Hartmut Goldschmidt, University Hospital of Heidelberg, Heidelberg, Germany; Laura Rosiñol, Joan Bladé, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona; Juan José Lahuerta, Hospital Universitario 12 de Octubre, Madrid, Spain; Michele Cavo, Paola Tacchetti, Elena Zamagni, Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Bologna, Italy; Michel Attal, Hopital Purpan, Toulouse; Philippe Moreau, University Hospital, Nantes, France; Avinash Desai, Janssen Global Services; Kevin Liu, Janssen Research and Development, Raritan, NJ; Dixie-Lee Esseltine, Millennium Pharmaceuticals, Cambridge, MA; Andrew Cakana, Janssen Research and Development, High Wycombe, United Kingdom; Helgi van de Velde, Janssen Research and Development, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.48.4626DOI Listing
September 2013

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.

Haematologica 2012 Dec 11;97(12):1925-8. Epub 2012 Jun 11.

Immuno-Hématologie Department, Hôpital Saint-Louis/Centre d'Investigations Cliniques, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2012.067793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685287PMC
December 2012

Analysis of two commercially available bortezomib products: differences in assay of active agent and impurity profile.

AAPS PharmSciTech 2011 Jun 1;12(2):461-7. Epub 2011 Apr 1.

Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana 47906, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1208/s12249-010-9554-1
Publisher Site
http://dx.doi.org/10.1208/s12249-010-9554-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134677PMC
June 2011

Genetic variation associated with bortezomib-induced peripheral neuropathy.

Pharmacogenet Genomics 2011 Mar;21(3):121-9

Johnson and Johnson Pharmaceutical Research and Development, Raritan, New Jersey 08869, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/FPC.0b013e3283436b45DOI Listing
March 2011

Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma.

Haematologica 2008 Dec 2;93(12):1908-11. Epub 2008 Sep 2.

Department of Hematology, University Hospital, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.13285DOI Listing
December 2008

Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.

J Pain Symptom Manage 2009 Feb 23;37(2):135-43. Epub 2008 Aug 23.

Developmental Therapeutics and GI Malignancies, University of Colorado Health Sciences Center, Aurora, Colorado 80045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpainsymman.2008.02.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856704PMC
February 2009

Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.

Haematologica 2007 Oct;92(10):1399-406

Johnson & Johnson Parmaceutical Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium.

View Article

Download full-text PDF

Source
http://www.haematologica.org/cgi/doi/10.3324/haematol.11534
Publisher Site
http://dx.doi.org/10.3324/haematol.11534DOI Listing
October 2007

Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.

J Clin Oncol 2006 Feb 23;24(6):976-82. Epub 2006 Jan 23.

Johnson & Johnson Pharmaceutical Services and Pharmaceutical Research and Development, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2005.04.0824
Publisher Site
http://dx.doi.org/10.1200/JCO.2005.04.0824DOI Listing
February 2006